Literature DB >> 10810039

Hypertrophic scar tissues and fibroblasts produce more transforming growth factor-beta1 mRNA and protein than normal skin and cells.

R Wang1, A Ghahary, Q Shen, P G Scott, K Roy, E E Tredget.   

Abstract

Transforming growth factor-beta1 is a well-known fibrogenic cytokine produced by many types of cells including dermal fibroblasts. To investigate whether this fibrogenic cytokine is involved in development of hypertrophic scar, transforming growth factor-beta1 gene expression was evaluated in small skin samples. Because a sufficient quantity of normal skin from patients with hypertrophic scar is not readily available, a reverse transcription-polymerase chain reaction technique was used. Quantitation of gene expression by reverse transcription-polymerase chain reaction is difficult partly due to the lack of suitable complementary RNA standards. We have established a convenient, reliable procedure to construct an internal standard for transforming growth factor-beta1 starting with a gene specific polymerase chain reaction product. After digestion of the polymerase chain reaction product with endonuclease, a small piece of cDNA from human procollagen alpha1(I) cDNA with compatible ends was inserted into the polymerase chain reaction-DNA fragment. The recombinant cDNA was re-amplified by polymerase chain reaction and subcloned into a plasmid containing bacteriophage T7 and T3 promoters. Complementary RNA was prepared from the recombinant plasmid and amplified by reverse transcription-polymerase chain reaction together with the tissue or cellular RNA. After amplification, the products were electrophoresed in an agarose gel containing ethidium bromide. The bands for internal standard and transforming growth factor-beta1 mRNA were scanned, digitized, and plotted against the amount of internal standard complementary RNA added in the reverse transcription-polymerase chain reaction. The number of mRNA molecules/cell was calculated. We examined the transforming growth factor-beta1 mRNA in hypertrophic scar tissue and in normal skin and found that hypertrophic scar tissues expressed five-fold more transforming growth factor-beta1 mRNA than normal skin per unit of wet weight. We used this procedure to quantitate transforming growth factor-beta1 mRNA expression in 5 pairs of fibroblast cultures derived from hypertrophic scar and normal skin. The results showed that hypertrophic scar fibroblast cultures contain significantly more molecules of mRNA for transforming growth factor-beta1 than normal cells (116 +/- 6 vs. 97 +/- 7, p = 0.017, n = 5). These results were supported by Northern analysis for transforming growth factor-beta1 mRNA in the cells and enzyme-linked immunosorbent assay for TGF-beta1 protein in fibroblast-conditioned medium. In conclusion, hypertrophic scar tissue and fibroblasts produce more mRNA and protein for transforming growth factor-beta1, which may be important in hypertrophic scar formation. The construction of the gene specific internal standard for reverse transcription-polymerase chain reaction is a simple and reliable procedure useful to quantitate gene expression in a small amount of tissue or number of cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10810039     DOI: 10.1046/j.1524-475x.2000.00128.x

Source DB:  PubMed          Journal:  Wound Repair Regen        ISSN: 1067-1927            Impact factor:   3.617


  37 in total

1.  Modelling the interaction of keratinocytes and fibroblasts during normal and abnormal wound healing processes.

Authors:  Shakti N Menon; Jennifer A Flegg; Scott W McCue; Richard C Schugart; Rebecca A Dawson; D L Sean McElwain
Journal:  Proc Biol Sci       Date:  2012-05-23       Impact factor: 5.349

2.  miR-145 Contributes to Hypertrophic Scarring of the Skin by Inducing Myofibroblast Activity.

Authors:  Christiane Gras; Dominica Ratuszny; Catarina Hadamitzky; Haijiao Zhang; Rainer Blasczyk; Constança Figueiredo
Journal:  Mol Med       Date:  2015-04-09       Impact factor: 6.354

3.  The potential of a niacinamide dominated cosmeceutical formulation on fibroblast activity and wound healing in vitro.

Authors:  Quenton Wessels; Etheresia Pretorius; Celeste M Smith; Hugo Nel
Journal:  Int Wound J       Date:  2012-08-14       Impact factor: 3.315

4.  Angiotensin II stimulates canonical TGF-β signaling pathway through angiotensin type 1 receptor to induce granulation tissue contraction.

Authors:  Tosan Ehanire; Licheng Ren; Jennifer Bond; Manuel Medina; George Li; Latif Bashirov; Lei Chen; George Kokosis; Mohamed Ibrahim; Angelica Selim; Gerard C Blobe; Howard Levinson
Journal:  J Mol Med (Berl)       Date:  2014-10-28       Impact factor: 4.599

Review 5.  Growth factor delivery strategies for rotator cuff repair and regeneration.

Authors:  Anupama Prabhath; Varadraj N Vernekar; Enid Sanchez; Cato T Laurencin
Journal:  Int J Pharm       Date:  2018-01-06       Impact factor: 5.875

6.  Smad ubiquitination regulatory factor 2 expression is enhanced in hypertrophic scar fibroblasts from burned children.

Authors:  Zhi Zhang; Celeste C Finnerty; Jing He; David N Herndon
Journal:  Burns       Date:  2011-09-14       Impact factor: 2.744

Review 7.  Hypertrophic Scarring: Current Knowledge of Predisposing Factors, Cellular and Molecular Mechanisms.

Authors:  Layla Nabai; Amir Pourghadiri; Aziz Ghahary
Journal:  J Burn Care Res       Date:  2020-01-30       Impact factor: 1.845

Review 8.  Cutaneous Scarring: Basic Science, Current Treatments, and Future Directions.

Authors:  Clement D Marshall; Michael S Hu; Tripp Leavitt; Leandra A Barnes; H Peter Lorenz; Michael T Longaker
Journal:  Adv Wound Care (New Rochelle)       Date:  2018-02-01       Impact factor: 4.730

9.  The Relationship between Proliferative Scars and Endothelial Function in Surgically Revascularized Patients.

Authors:  Murat Ziyrek; Sinan Şahin; Zeydin Acar; Onur Şen
Journal:  Balkan Med J       Date:  2015-10-01       Impact factor: 2.021

Review 10.  Biology and principles of scar management and burn reconstruction.

Authors:  Edward E Tredget; Benjamin Levi; Matthias B Donelan
Journal:  Surg Clin North Am       Date:  2014-08       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.